Jan 5, 2009 - CyDex Pharmaceuticals, Inc. today announced that Prism Pharmaceuticals' NEXTERONE, which recently received new drug application (NDA) approval from the U.S. FDA, is based on the patent-protected CyDex CAPTISOL technology platform. NEXTERONE is the first CyDex proprietary product to achieve the milestone of NDA approval.
The details can be read here.
No comments:
Post a Comment